NFCR Press Release NFCR Writer David Perry August 6, 2018 In an attempt to bolster the numbers of minorities in cancer research, the Cleveland-based Case Western Reserve University School of Medicine (CaseMed), […]
NFCR Press Release NFCR Writer David Perry July 21, 2018 In both mouse and culture-dish experiments, researchers at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center found that a new line of […]
Clarient & Health Discovery Corp.’s New Diagnostic Test For Prostate Cancer Has 97% Specificity, Study Says
ALISO VIEJO, Calif. & SAVANNAH, Ga.–(BUSINESS WIRE)–Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, and Health Discovery Corporation (HDC) (OTCBB: […]
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. With a mission to support industry-wide […]
Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.